Abstract:Background In most western countries, ischemic heart disease (IHD) is the most common cause of death and a major cause of hospital admissions. Conventional drug therapy is designed to effect through anti-oxidation, anti-apoptosis, anti-inflammation and anti-lipidemia to protect against IHD. Since hydrogen sulfide has been reported to induce angiogenesis in vitro and in vivo , we investigated the pro-angiogenic effect of SPRC, a novel water-soluble modulator of endogenous hydrogen sulfide, to provide experimental basis for angiogenesis-mediated drug therapy of IHD. In addition, we revealed STAT3-mediated mechanism involved in hydrogen sulfide-induced angiogenesis. Methods Cell viability assay, cell proliferation assay, cell adhesion assay, wound healing assay, transwell migration assay and tube formation assay were carried out to determine the pro-angiogenic effect of SPRC on endothelial cells in vitro . Matrigel plug assay, rat aortic ring assay, CAM assay and sponge implantation assay were carried out to determine the pro-angiogenic effect of SPRC in vivo . Hind-limb ischemia model and myocardial infarction model were induced to explore the angiogenesis in ischemic condition by laser doppler imaging and angiography. Western blot and immunofluorescence were used to detect the level and location of proteins, respectively. EMSA and CHIP were performed to determine the activation of STAT3 and its downstream promoters. Results SPRC promoted cell proliferation, adhesion, migration and tube formation of primary HUVEC and increased angiogenesis ex vivo and in vivo under both normal and ischemic conditions. In SPRC-induced angiogenesis, phosphorylation of VEGFR2 and STAT3 was elevated significantly, followed by activation of some signal molecules, such as MAPK and Akt. The interaction between VEGFR2 and STAT3 was enhanced after SPRC-treatment. Meanwhile, SPRC induced translocation of STAT3 to nucleus, followed by transcriptional activation of downstream promoters, especially vegf promoter. The critical roles of STAT3 in mediating the pro-angiogenic effect of SPRC were confirmed by RNA interference. Conclusion Based on the proved pro-angiogenic effect of hydrogen sulfide, we proposed and tested SPRC-induced angiogenesis in vitro and in vivo to provide experimental basis for angiogenesis-mediated drug therapy of IHD. More important, we investigated the relative mechanism of STAT3 involved in SPRC-induced angiogenesis, including interaction with VEGFR2 and translocation into nucleus to active transcription.

S-Propargyl-cysteine (SPRC) Attenuated Lipopolysaccharide-Induced Inflammatory Response in H9c2 Cells Involved in a Hydrogen Sulfide-Dependent Mechanism

S-propargyl-cysteine Attenuates Inflammatory Response in Rheumatoid Arthritis by Modulating the Nrf2-ARE Signaling Pathway

S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-κB pathway in rats

Cardioprotection of H2S by downregulating iNOS and upregulating HO-1 expression in mice with CVB3-induced myocarditis

S-Propargyl-Cysteine Protects Both Adult Rat Hearts and Neonatal Cardiomyocytes from Ischemia/Hypoxia Injury: the Contribution of the Hydrogen Sulfide-Mediated Pathway

SPRC Suppresses Experimental Periodontitis by Modulating Th17/Treg Imbalance

H2S Protects Lipopolysaccharide-Induced Inflammation by Blocking NFκB Transactivation in Endothelial Cells.

Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction.

Cardioprotective Effects of a Novel Hydrogen Sulfide Agent-Controlled Release Formulation of S-propargyl-cysteine on Heart Failure Rats and Molecular Mechanisms.

S-Propargyl-cysteine Exerts a Novel Protective Effect on Methionine and Choline Deficient Diet-Induced Fatty Liver via Akt/Nrf2/HO-1 Pathway.

P13 S-Propargyl-Cysteine (SPRC) promoted angiogenesis under both normal and ischemic conditions: Possible STAT3-mediated mechanism

SPRC Protects Hypoxia and Re-Oxygenation Injury by Improving Rat Cardiac Contractile Function and Intracellular Calcium Handling.

Protective effects of cysteine analogues on acute myocardial ischemia: Novel modulators of endogenous H2S production

S-Propargyl-Cysteine Attenuates Diabetic Cardiomyopathy in db/db Mice Through Activation of Cardiac Insulin Receptor Signaling

S-Propargyl-cysteine Exerts a Novel Protective Effect on Methionine and Choline Deficient Diet-Induced Fatty Liver Via Akt/Nrf2/HO-1 Pathway

Silencing of specificity protein 1 protects H9c2 cells against lipopolysaccharide-induced injury via binding to the promoter of chemokine CXC receptor 4 and suppressing NF-κB signaling

H2S Donor, S-propargyl-cysteine, Increases CSE in SGC-7901 and Cancer-Induced Mice: Evidence for a Novel Anti-Cancer Effect of Endogenous H2S?

S-propargyl-cysteine Delays the Progression of Atherosclerosis and Increases Enos Phosphorylation in Endothelial Cells.

Hydrogen Sulfide Attenuates Oxidative Stress-Induced NLRP3 Inflammasome Activation Via S-sulfhydrating C-Jun at Cys269 in Macrophages

S-propargyl-cysteine promotes the stability of atherosclerotic plaque via maintaining vascular muscle contractile phenotype

P100 SPRC-leonurine Conjugate Alleviates Ischemia Induced Cardiac Fibrosis Through ROS-Stat3 Pathway